How Does Zepbound Work? A Complete Guide

Key Takeaways

• Zepbound contains tirzepatide, which acts on two hormone pathways involved in appetite, GIP and GLP-1.
• Tirzepatide may help reduce hunger and cravings, supporting weight loss.
• Zepbound helps eligible adults lose weight and keep it off, alongside a lower-calorie diet and more physical activity.
• Zepbound and Mounjaro contain the same medicine, but they're different products with different uses.
• A licensed provider reviews your health history and required labs before prescribing, then reviews your progress before each refill.

Some days hunger seems to call the shots, and you're far from the only one who feels that way. When researchers surveyed US adults with obesity, 49% named controlling hunger as a barrier to starting a weight-loss effort. Hunger runs on signals your body sends, and Zepbound works on two of them.

How Does Zepbound Help With Hunger?

Zepbound contains tirzepatide, a medicine that activates the receptors for two natural hormones, GIP and GLP-1. Both are involved in appetite, so tirzepatide works on two hunger signals at once.

Approved tirzepatide injections reduce calorie intake, likely through their effects on appetite. In a six-week study of adults who were overweight or living with obesity, tirzepatide reduced hunger before meals and food cravings. That can mean fewer moments when cravings set the agenda.

Tell your provider what hits hardest, whether that's hunger between meals, cravings or portion sizes. Your plan can be shaped around it.

Start with an evaluation

What Results Can Look Like

In a 72-week study on the Zepbound label, people taking Zepbound 15 mg lost an average of 20.9% of their starting weight, and 90.9% of them lost at least 5%. Everyone in the study also had support with a lower-calorie diet and more activity. Your results will be your own, so your provider reviews your progress before each refill and adjusts your plan as needed.

What Is Zepbound Approved For?

Zepbound is approved for weight loss and long-term weight maintenance in adults living with obesity, or who are overweight and have at least one weight-related health condition. It's used alongside a lower-calorie diet and more physical activity. It's also approved to treat moderate to severe obstructive sleep apnea in adults with obesity.

LIV offers Zepbound, and your provider reviews whether it fits your health history and goals. If you're also weighing compounded tirzepatide, which LIV offers too, our compounded tirzepatide guide explains the difference.

Is Zepbound the Same as Mounjaro?

They contain the same medicine, tirzepatide, but they're different products. Mounjaro's label covers one use: improving blood sugar control in adults with type 2 diabetes, alongside diet and exercise. Zepbound's label covers weight loss and obstructive sleep apnea.

Side Effects and Safety Notes

The most common side effects listed on the Zepbound label are stomach-related: nausea, diarrhea, vomiting, constipation, abdominal pain and indigestion. Reactions where you inject can also happen.

Zepbound isn't right for everyone. Before prescribing, your provider will ask about:

• Thyroid history: a personal or family history of medullary thyroid cancer or MEN 2.
• Past conditions: pancreatitis, gallbladder disease or kidney problems.
• Other medicines: especially diabetes medicines that can lower blood sugar.
• Allergies: any serious allergic reaction to tirzepatide or another medicine.

Contact your provider promptly about severe or lasting stomach pain, ongoing vomiting or signs of dehydration.

Starting Zepbound With Your Provider

Your plan starts with an evaluation. A licensed provider reviews your health history, the medicines you take and your required labs, then decides whether Zepbound is right for you and at what strength.

Zepbound is a weekly injection under the skin of your abdomen or thigh, or another person can give it in the back of your upper arm. Move to a new spot with each dose. A pen is for one person only, never shared, even with a new needle. The injection-site guide covers the details.

Before each refill, you tell LIV how you're doing, and your provider reviews your progress and adjusts your plan as needed. Bring up changes in appetite, any side effects and anything that's hard about the routine.

Talk Through Your Goals With a Provider

Start with what you'd like help with, whether that's hunger, cravings or keeping weight off. An evaluation is where a licensed provider reviews your history and helps you decide whether Zepbound is right for you.

Frequently Asked Questions

How does Zepbound work in the body?

Zepbound contains tirzepatide, which activates the receptors for two natural hormones involved in appetite, GIP and GLP-1. The Zepbound label describes GLP-1 as a natural regulator of appetite and calorie intake. It says nonclinical studies suggest GIP may add to that, and that in animal studies tirzepatide activated nerve cells in brain areas that regulate appetite.

What did studies find about tirzepatide and hunger?

In a six-week study, adults who were overweight or living with obesity and took tirzepatide reported less hunger before meals and fewer food cravings than those taking a placebo. It was a short, early-stage study, and results vary from person to person, so your provider will check in on how you're doing.

Where do the weight-loss figures come from?

From Study 1 in the Zepbound prescribing information (Table 2), the SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022). It enrolled 2,539 adults with obesity, or excess weight and a related health condition, who didn't have type 2 diabetes. Every group had support with a lower-calorie diet and more activity.

The figures are for the 15 mg and placebo groups, not every dose. On placebo, average weight loss was 3.1%, and 34.5% of people lost at least 5%. The estimates include people who stopped treatment, doses were increased gradually, and the study dose isn't a dosing recommendation. Individual results vary.

Is Zepbound the same as Mounjaro?

They contain the same medicine and are different products with different labels. Mounjaro's single approved use is blood sugar control in adults with type 2 diabetes. Zepbound's are weight loss with long-term maintenance, and moderate to severe obstructive sleep apnea in adults with obesity.

Is Zepbound the same as compounded tirzepatide?

They share an active ingredient, but they're different products. Zepbound is an FDA-approved tirzepatide injection. Compounded tirzepatide is prepared for one patient by a licensed pharmacy, and it isn't a generic version of Zepbound. Compounded medicines aren't FDA-approved, and the FDA doesn't review their safety, effectiveness or quality before they're marketed.

What side effects showed up in the Zepbound trials?

In the label's weight trials, nausea was reported by 8% of people on placebo and by 25% to 29% of people taking Zepbound, depending on the dose. Injection site reactions were reported by 2% on placebo and 6% to 8% on Zepbound. Your provider can talk through how to manage side effects.

What does the boxed warning on Zepbound say?

The Zepbound label carries a boxed warning about thyroid C-cell tumors. Tirzepatide caused these tumors in rats; it isn't known whether Zepbound does in people, including a type called medullary thyroid cancer. Zepbound isn't for anyone with a personal or family history of medullary thyroid cancer or MEN 2, or a serious allergy to tirzepatide or its ingredients.

Tell your provider about a lump in your neck, trouble swallowing, shortness of breath or hoarseness that doesn't go away. The label also asks you to tell your care team you take Zepbound before any planned surgery or procedure. The label also notes that routine blood tests (calcitonin) or thyroid ultrasound are of uncertain value for catching these tumors early.

References

Eli Lilly and Company. (2026). Zepbound (tirzepatide) injection, for subcutaneous use: Prescribing information (revised 4/2026). DailyMed, U.S. National Library of Medicine. Clinical Pharmacology, Boxed Warning, Contraindications, Warnings and Precautions, Adverse Reactions and Clinical Studies (Study 1, Table 2). Read 2026-08-20; Table 2 values verified September 16, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b

Eli Lilly and Company. (2026). Mounjaro (tirzepatide) injection, for subcutaneous use: Prescribing information (revised 4/2026). DailyMed, U.S. National Library of Medicine. Read 2026-08-20. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0

Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/

Kaplan, L. M., Golden, A., Jinnett, K., Kolotkin, R. L., Kyle, T. K., Look, M., et al. (2018). Perceptions of barriers to effective obesity care: Results from the National ACTION Study. Obesity, 26(1), 61-69. https://pubmed.ncbi.nlm.nih.gov/29086529/

Tirzepatide on ingestive behavior in adults with overweight or obesity: A randomized 6-week phase 1 trial. (2025). Nature Medicine. doi:10.1038/s41591-025-03774-9. Read September 11, 2026. https://www.nature.com/articles/s41591-025-03774-9

U.S. Food and Drug Administration. (2026). Compounding and the FDA: Questions and answers. Read 2026-08-20. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers